Insight on Itropine for Physicians

In medicine, atropine is a broad spectrum anticholinergic agent. As a topical ophthalmic, it has many different concentrations and indications for use. Itropine has a very low concentration and has been investigated to successfully lower myopia progression in clinical trials. These studies have assisted in confirming its safety, efficacy, and benefits within the realm of myopia control.

Among various concentrations Itropine reduces myopia progression by 30-50%. Itropine also works well to eliminate adverse effects and avoid rebound progression noted in other formulations.

In myopia, worsening vision and refractive error occurs due to axial elongation, potentially caused by peripheral hyperopic defocus. Using atropine treatment such as Itropine is a commonly established practice for myopia control. Studies convey that reducing axial elongation is a probable mechanism, possibly via accommodative or muscarlic pathways affecting the retinal, scleral, and/or choroidal receptors.

Despite the ambiguity, Itropine does ensure reduction in progression as it contributes to reducing the spherical error trend in a refractive manner. This manifests to minimizing future risks of high myopia related ocular complications.